I'm studying cell survival in primary dopaminergic neurons upon toxin challenge with MPP+ (in vitro Parkinson's Disease model). I want to test whether a range of compounds can reduce dopaminergic cell death in this assay.

I'm in doubt how I should handle the compound to protect myself and my colleagues sufficiently?

Similar questions and discussions